Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
MELBOURNE, Australia, Feb. 13, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Nasdaq: TLX, Telix, the Company) today announces that the United Kingdom (UK) Medicines and...
-
Minneapolis, MN, Feb. 12, 2025 (GLOBE NEWSWIRE) -- Sezzle Inc. (NASDAQ:SEZL) (Sezzle or Company) // Purpose-driven digital payment platform, Sezzle, will release its fourth quarter 2024 results after...
-
Fully Funded and Positioned for Commercialization in FY2026 MCDONALD, Tenn., Feb. 10, 2025 (GLOBE NEWSWIRE) -- Amaero International Limited (ASX:3DA) (“Amaero” or the “Company”) a leading U.S....
-
Perth, Feb. 11, 2025 (GLOBE NEWSWIRE) -- HALF YEAR RESULTS INVESTOR WEBINAR / CALL Perth, Western Australia/ February 11, 2025/Perseus Mining Limited (ASX/TSX: PRU) is hosting an investor webinar...
-
Successful detection of brain metastases using RAD 101 (18F-Pivalate) in a novel multiparametric imaging methodology (PET-mpMRI) study across 22 patients.All brain metastases, regardless of whether...
-
– Funds to be used primarily to advance development of ATH434 in Parkinsonian Disorders – – Capital raising was strongly supported by domestic and international institutional investors – MELBOURNE,...
-
MELBOURNE, Australia and PRINCETON, N.J., Feb. 07, 2025 (GLOBE NEWSWIRE) -- Opthea Limited (ASX/NASDAQ:OPT, “Opthea”, the “Company”), a clinical-stage biopharmaceutical company developing novel...
-
L'investissement contribuera aux travaux de faisabilité concernant les infrastructures clés entre les mines et l'usine de traitement de Chibougamau FAITS SAILLANTS : Cygnus a reçu...
-
Investment will contribute towards feasibility work for key infrastructure between the mines and the Chibougamau Processing Facility HIGHLIGHTS: Cygnus has received conditional approval form the...
-
MELBOURNE, Australia, and PRINCETON, N.J., Feb. 06, 2025 (GLOBE NEWSWIRE) -- Opthea Limited (ASX/NASDAQ:OPT, “Opthea”, the “Company”), a clinical-stage biopharmaceutical company developing novel...